OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme

Abstract Background EIMs are common in patients with UC and associated impaired quality of life. This analysis evaluated the impact treatment selective Janus kinase 1 inhibitor UPA on moderate-to-severe UC. Methods Data were included from two induction studies (U-ACHIEVE Induction [NCT02819635] U-ACCOMPLISH [NCT03653026]) a maintenance study Maintenance). Patients randomised 2:1 to 8 weeks’ 45 mg once daily (QD) or placebo. clinical response re-randomised (1:1:1) 52 15 30 QD, The presence (peripheral arthropathy, axial episcleritis, uveitis, iritis, erythema nodosum, pyoderma gangrenosum, Sweet’s syndrome, oral aphthous ulcers, primary sclerosing cholangitis, autoimmune hepatitis, venous thromboembolism, chronic obstructive pulmonary disease, bronchiectasis, nephrolithiasis anaemia) was captured EIM form at start (baseline) every visit up Week 52. results pooled for analysis. Results At baseline, 25.0% 26.5% QD placebo groups had ?1 EIM, while 24.3%, 26.6% 24.8% placebo, respectively, (Table 1). most baseline anaemia, peripheral arthropathy arthropathy; all other reported <2% proportion reporting resolution any axial) anaemia numerically greater than (Figure 1A). Resolution significantly increased (p<0.001), versus 1B). In achieving (p=0.010), higher same true (p=0.019 placebo; Figure Conclusion is effective resolving symptom improved following after mg, dose providing statistically significant improvements